Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 16.98
+0.04 (0.24%)
Apr 2, 2026, 4:08 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 208 employees as of June 30, 2025.
Employees
208
Change
n/a
Growth
n/a
Revenue / Employee
10.85K HKD
Profits / Employee
-1.93M HKD
Market Cap
18.02B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 208 | - | - |
| Dec 31, 2024 | 231 | 12 | 5.48% |
| Dec 31, 2023 | 219 | -59 | -21.22% |
| Dec 31, 2022 | 278 | 12 | 4.51% |
| Dec 31, 2021 | 266 | 10 | 3.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,165 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,469 |
| Everest Medicines | 722 |
| Ascentage Pharma Group International | 605 |
| Lepu Biopharma | 546 |
| HBM Holdings | 210 |
| Duality Biotherapeutics | 191 |
Ascletis Pharma News
- 25 days ago - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity - PRNewsWire
- 7 weeks ago - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development - PRNewsWire
- 2 months ago - Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes - PRNewsWire
- 2 months ago - Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - PRNewsWire
- 3 months ago - Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes - PRNewsWire
- 3 months ago - Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor - PRNewsWire
- 4 months ago - Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight - PRNewsWire
- 4 months ago - Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - PRNewsWire